Elafibranor | PPARalpha/delta agonist
NMR (Conforms)
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 5 mg | $65.00 | ||
| 25 mg | $235.00 |
Elafibranor (923978-27-2) is a dual PPARα/δ agonist (EC50 PPARα = 10-20 nM; PPARδ = 100-150 nM).1 It was able to decrease plasma triglycerides levels1, increase HDL cholesterol levels in human studies1, and improve hepatic and peripheral insulin sensitivity2. Elafibranor’s antidiabetic effects in db/db were without the adverse cardiac effects seen in PPARγ agonism.3 Elafibranor has also been shown to have therapeutic promise in the treatment of nonalcoholic steatohepatitis (NASH).4-6
References/Citations:
1) Cariou et al. (2011) Effects of the New Dual PPARα/δ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism; Diabetes Care 34 2008
2) Cariou et al. (2013) Dual peroxisome proliferator receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects; Diabetes Care 36 2923
3) Hanf et al. (2014) The dual peroxisome proliferator-activated alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects.; Diab. Vasc. Dis. Res. 11 440
4) Staels et al. (2013) Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha-delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis; Hepatology 58 1941
5) Ratziu et al. (2016) Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.; Gastroenterology. 39 2951
6) Boeckmans et al. (2019) Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH.; Pharmacol. Res. 114 377
NMR (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Elafibranor (923978-27-2) is a dual PPARα/δ agonist (EC50 PPARα = 10-20 nM; PPARδ = 100-150 nM).1 It was able to decrease plasma triglycerides levels1, increase HDL cholesterol levels in human studies1, and improve hepatic and peripheral insulin sensitivity2. Elafibranor’s antidiabetic effects in db/db were without the adverse cardiac effects seen in PPARγ agonism.3 Elafibranor has also been shown to have therapeutic promise in the treatment of nonalcoholic steatohepatitis (NASH).4-6
References/Citations:
1) Cariou et al. (2011) Effects of the New Dual PPARα/δ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism; Diabetes Care 34 2008
2) Cariou et al. (2013) Dual peroxisome proliferator receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects; Diabetes Care 36 2923
3) Hanf et al. (2014) The dual peroxisome proliferator-activated alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects.; Diab. Vasc. Dis. Res. 11 440
4) Staels et al. (2013) Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha-delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis; Hepatology 58 1941
5) Ratziu et al. (2016) Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.; Gastroenterology. 39 2951
6) Boeckmans et al. (2019) Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH.; Pharmacol. Res. 114 377
Related products
-
HPI-1 | Hedgehog pathway inhibitor
From $75.00CAS:599150-20-6 (anhydrous)Catalog Number:10-4522Activity:Hedgehog pathway inhibitorChemical Name:2-Methoxyethyl 1,4,5,6,7,8-hexahydro-4-(3-hydroxyphenyl)-7-(2-methoxyphenyl)-2-methyl-5-oxo-3-quinolinecarboxylateMolecular Weight:463.52 (anhydrous)Molecular Formula:C27H29NO6 xH20Solubility:Soluble in DMSO (up to 25 mg/ml) or in Ethanol (up to 25 mg/ml).Physical Properties:Yellow solidPurity:>98% by TLC
NMR (conforms)Storage Temperature:-20°Stability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months.Shipping Code:RT -
Pomalidomide | Cereblon ubiquitination inhibitor
From $50.00CAS:19171-19-8Catalog Number:10-2768Activity:Cereblon ubiquination inhibitorChemical Name:1,3-Dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline; 3-amino-N-(2,6-dioxo-3-piperidyl)phthalamideMolecular Weight:273.24Molecular Formula:C13H11N3O4Solubility:Soluble in DMSO (up to 50 mg/ml).Physical Properties:Yellow solidPurity:98% by TLC
NMR (Conforms)Storage Temperature:-20°Stability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month.Shipping Code:RT -
BI 2536 | Dual Plk/BRD4 inhibitor – Destabilizes Myc
From $75.00CAS:755038-02-9Catalog Number:10-4121Activity:Dual Plk/BRD4 inhibitor – Destabilizes MycChemical Name:4-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamideMolecular Weight:521.67Molecular Formula:C28H39N7O3Solubility:Soluble in DMSO (up to 20 mg/ml) or in Ethanol (up to 25 mg/ml)Physical Properties:Off-white solidPurity:97% by HPLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.Shipping Code:RT
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
